About this Presentation

For years, the biologics industry has struggled with inefficient microbial expression systems for producing proteins and antibodies that they need to manufacture new biopharmaceuticals. Difficulties with low titers, poor product quality, impurities in samples, and capacity constraints are just some of the challenges that scientists have with legacy systems.

Scientists at KBI Biopharma, led by Erik Nordwald, PhD, worked tirelessly for over two years to develop a novel state-of-the-art microbial cell line development platform that addresses these challenges. The new PUREplatform™ solution provides all the functionality that scientists need for optimal therapeutic protein production and development.

In this webinar, Dr. Norwald discusses how the groundbreaking PUREplatform improves microbial therapeutic protein expression. You’ll learn how PUREplatform can transform microbial drug substance production at a fraction of the scales previously needed.

Specific learning objectives include:

• Understand the inherent challenges and risks associated with microbial biologic development.

• Gain insights into the constraints faced during microbial biologics development, and new strategies to streamline timelines.

•  Discover how PUREcoli™ plays a pivotal role in mitigating many of these challenges from the outset.

• Learn how PUREcoli addresses complexities in microbial biologic development, setting the stage for simpler processes down the line.